

**Anti-CD34 Reference Antibody (ITRI patent anti-CD34)
Recombinant Antibody
Catalog # APR10804****Specification**

Anti-CD34 Reference Antibody (ITRI patent anti-CD34) - Product Information

Application	FC, Kinetics, Animal Model
Primary Accession	P28906
Reactivity	Human, Mouse
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	145 KDa


Anti-CD34 Reference Antibody (ITRI patent anti-CD34) - Additional Information**Target/Specificity**
CD34**Endotoxin**
< 0.001EU/ µg,determined by LAL method.**Conjugation**
Unconjugated**Expression system**
CHO Cell**Format**
Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.**Anti-CD34 Reference Antibody (ITRI patent anti-CD34) - Protein Information****Name** CD34**Function**
Possible adhesion molecule with a role in early hematopoiesis by mediating the attachment of stem cells to the bone marrow extracellular matrix or directly to stromal cells. Could act as a scaffold for the attachment of lineage specific glycans, allowing stem cells to bind to lectins expressed by stromal cells or other marrow components. Presents carbohydrate ligands to selectins.**Cellular Location**
Membrane; Single-pass type I membrane protein.**Tissue Location**
Selectively expressed on hematopoietic progenitor cells and the small vessel endothelium of a variety of tissues

Anti-CD34 Reference Antibody (ITRI patent anti-CD34) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

Anti-CD34 Reference Antibody (ITRI patent anti-CD34) - Images



Anti-CD34 Reference Antibody (ITRI patent anti-CD34) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-CD34 Reference Antibody (ITRI patent anti-CD34) is more than 95%, determined by SEC-HPLC.